Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice.

Authors

Iris Hochstenbach, Julie J M Hamm, Eva Rademaker, Arend G J Aalbers, Djamila Boerma, Wilhelmina M U van Grevenstein, Patrick H J Hemmer, Ignace H J T De Hingh, Niels F M Kok, Jurriaan B Tuynman, Eva V E Madsen, Johannes H W de Wilt, Esther C J Consten, Henderik L van Westreenen, Pieter J Tanis, COLOPEC Collaborators Group, Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative

Published in

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Volume 28. Issue 9. Pages e70614.

Abstract

The randomized COLOPEC trial demonstrated no benefit of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in preventing peritoneal metastases in locally advanced colon cancer. Because all patients underwent a diagnostic laparoscopy at 18 months, the study lacked a true control arm, leaving the effect of early detection and treatment compared with standard care uncertain. This study aimed to compare long-term oncological outcomes between patients treated in the COLOPEC trial and patients treated in routine care.
Patients who underwent curative resection for c/pT4 or perforated colon cancer in the COLOPEC trial were compared with a retrospective control cohort that included all colon cancer resections performed in 2014-2015, in 50 Dutch hospitals. All 202 trial patients were matched 1:1 to 202 control patients using propensity score matching.
Following treatment in both arms of the COLOPEC trial, compared to the matched control cohort, 5-year overall survival was 70.2% versus 72.8% (p = 0.77). Five-year disease-free survival was 62.1% versus 65.2% (p = 0.31) and five-year cumulative incidence of peritoneal metastases was 24.4% Versus 9.5% (p < 0.001). Cytoreductive surgery with HIPEC for peritoneal recurrence was performed in 28 (13.9%) versus 7 patients (3.5%; p < 0.001).
Despite increased detection and more frequent treatment of peritoneal metastases in the COLOPEC trial, 5-year overall and disease-free survival were comparable to routine practice.

PMID:
42755020
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.